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A seasonal reassortant A(H1N2) influenza virus har-
bouring genome segments from seasonal influenza 
viruses A(H1N1)pdm09 (HA and NS) and A(H3N2) (PB2, 
PB1, PA, NP, NA and M) was identified in March 2018 
in a 19-months-old patient with influenza-like illness 
(ILI) who presented to a general practitioner partici-
pating in the routine sentinel surveillance of ILI in 
the Netherlands. The patient recovered fully. Further 
epidemiological and virological investigation did not 
reveal additional cases.
In the routine sentinel general practitioner (GP) surveil-
lance of influenza in the Netherlands, a new seasonal 
reassortant A(H1N2) influenza virus was identified in 
natural human infection in March 2018. Here we report 
the case detection, molecular characterisation of the 
virus and the results of follow-up epidemiological and 
virological investigation.
Influenza surveillance in the Netherlands 
In the Netherlands, influenza surveillance is a collabo-
rative effort of the National Influenza Centre (NIC) (con-
sisting of the National Institute for Public Health and 
the Environment (RIVM) in Bilthoven and the Erasmus 
University Medical Centre (Erasmus MC) in Rotterdam) 
and the NIVEL Primary Care Database sentinel sur-
veillance in Utrecht [1,2]. The GPs participating in the 
sentinel surveillance report weekly the incidence of 
influenza-like illness (ILI) according to the case defi-
nition by Pel (sudden onset of symptoms, fever of at 
least 38 °C and at least one of the following: cough, 
rhinorrhoea, sore throat, frontal headache, retroster-
nal pain, myalgia) [3]. They take nose and throat swabs 
for influenza virus detection by real-time RT-PCR at the 
NIC from a systematic selection of patients presenting 
with ILI or another acute respiratory infection (ARI). 
Diagnostic GP and hospital laboratories forward influ-
enza virus-positive specimens for further characterisa-
tion to the NIC. All influenza viruses are subtyped by 
real-time RT-PCR and a subset is further characterised 
by sequencing, virus isolation and haemagglutination 
inhibition and neuraminidase inhibition assays.
Case detection 
In the Netherlands, the 2017/18 influenza epidemic has 
been dominated by influenza viruses of the B/Yamagata 
lineage (Figure 1). Since the beginning of March, both 
A(H3N2) and A(H1N1)pdm09 influenza viruses have 
been increasingly detected. By week 11/2018 the inci-
dence of ILI had been above the epidemic threshold for 
14 weeks. In week 10 on 5 March, a sentinel GP was 
consulted for a 19 months-old patient with acute onset 
of ILI on 2 March characterised by fever, malaise, sore 
throat, coughing, shortness of breath, rhinorrhoea and 
diarrhoea.
Virus characterisation 
MinION nanopore whole genome sequencing confirmed 
on 18 March that the patient was infected by a seasonal 
reassortant A(H1N2) influenza virus, with the HA and 
non-structural (NS) segments derived from seasonal 
A(H1N1)pdm09 influenza virus and all other segments 
(polymerase components PB2, PB1 and PA, nucleopro-
tein (NP), NA and matrix (M)) from seasonal influenza 
A(H3N2) virus. The genome sequence of influenza virus 
A/Netherlands/10407/2018 H1N2 is available from the 
GISAID EpiFlu database (EPI_ISL_304183).
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The HA and NA segments were highly similar to those of 
the 2018 A(H1N1)pdm09 and A(H3N2) influenza viruses 
in the Netherlands detected through the sentinel sur-
veillance (Figure 2 and Figure 3).
Because no full genomes of other 2018 Dutch influ-
enza viruses were available, the other segments were 
compared with those from 100 A(H1N1)pdm09 and 200 
A(H3N2) influenza viruses collected in 2018 from coun-
tries in the World Health Organization European Region. 
The NS segment was closely related to NS segments 
of 2018 A(H1N1)pdm09 viruses (Figure 4) and the PB2, 
PB1, PA, NP and M segments were closely related to 
the corresponding segments of 2018 A(H3N2) viruses 
(Supplement 1).
We observed a number of nucleotide substitutions 
in the segments of this influenza A(H1N2) virus com-
pared with the consensus sequences of other 2018 
viruses. However, the majority of them were silent; 
unique amino acid substitutions were only identified in 
the M2 protein (V68I and D88N) and in the NA protein 
(I30L). M2 harboured S31N, similar to all recent influ-
enza A(H3N2) viruses, causing resistance against the 
adamantane class of influenza antiviral drugs. In NA, 
no amino acid substitutions were detected that have 
been associated previously with reduced sensitivity 
to NA inhibitors, again similar to the vast majority of 
recent influenza A(H3N2) viruses. Furthermore, eight 
influenza A(H3N2) viruses isolated during the 2017/18 
season in the sentinel surveillance in the Netherlands 
that had an NA protein sequence similar to that of the 
influenza A(H1N2) virus were tested for susceptibil-
ity to oseltamivir and zanamivir in the neuraminidase 
inhibition assay as described [4]. All eight were inhib-
ited normally by oseltamivir (median IC50: 0.20; range: 
0.17–0.28 nM) and zanamivir (median IC50: 0.31; range: 
0.21–0.38 nM). Together, these findings indicate that 
this influenza A(H1N2) virus was highly likely to be 
sensitive to oseltamivir and zanamivir. As the HA pro-
tein sequence was similar to that of recent influenza 
A(H1N1)pdm09 viruses and interim 2017/18 season 
estimates of vaccine effectiveness for Europe showed 
55–68% effectiveness in preventing laboratory-con-
firmed influenza A(H1N1)pdm09 virus infection [5], we 
consider that the currently used vaccine for the north-
ern hemisphere offers protection against the influenza 
A(H1N2) virus.
Unfortunately, attempts to isolate the A(H1N2) virus 
in cell culture and embryonated chicken eggs were 
unsuccessful, probably because of the low viral 
load in the clinical specimen at the time of sampling 
as shown by a Ct value of 29.2 in the RT-PCR target-
ing M. Experimental reassortant influenza virus with 
HA from A(H1N1)pdm09 influenza virus and the other 
segments from influenza A(H3N2) virus showed only 
slightly attenuated growth characteristics in human 
Figure 1
ILI incidence and number of specimens from patients with ILI collected by sentinel general practitioners in which influenza 
virus was detected, the Netherlands, 21 March 2018 (n = 395)
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Figure 2
Phylogenetic analysis of the influenza A(H1N2) virus haemagglutinin genome segment in the context of a reference 
influenza virus data seta and recent influenza viruses from the Netherlands
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HA: haemagglutinin.
a Reference dataset provided by the World Health Organization Collaborating Centre London through the European Centre for Disease 
prevention and Control for seasonal phylogenetic analysis. We gratefully acknowledge the authors, originating and submitting laboratories of 
the sequences retrieved from GISAID’s Epiflu database that were used in this analysis (Supplement 2).
The evolutionary history was inferred using the neighbour-joining method [12]. The optimal tree is shown. The percentage of replicate trees 
in which the associated taxa clustered together in the bootstrap test (1,000 replicates) is shown next to the branches [13]. The tree is drawn 
to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary 
distances were computed using the Jukes-Cantor method [14] and are in the units of the number of base substitutions per site. All ambiguous 
positions were removed for each sequence pair. Evolutionary analyses were conducted in MEGA7 [15]. Common amino acid substitutions 
(black: HA1, orange: HA2) compared with the root virus are shown at branches that characterise the cluster of viruses after that branch. HA 
of the influenza A(H1N2) virus (red dot) clustered with HA of recent 2018 Dutch clade 6B.1 A(H1N1)pdm09 influenza viruses characterised by 
common amino acid substitution V250A.
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Figure 3
Phylogenetic analysis of the influenza A(H1N2) virus neuraminidase genome segment in the context of a reference 
influenza virus data seta and recent influenza viruses from the Netherlands
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a Reference dataset provided by the World Health Organization Collaborating Centre London through the European Centre for Disease 
prevention and Control for seasonal phylogenetic analysis. We gratefully acknowledge the authors, originating and submitting laboratories of 
the sequences retrieved from GISAID’s Epiflu database that were used in this analysis (Supplement 2).
Phylogenetic analysis was carried out as described in the Figure 2 legend. Common amino acid substitutions compared with the root virus 
are shown at branches that characterise the cluster of viruses after that branch. The NA of the influenza A(H1N2) virus (red dot) clustered with 
NA of recent 2018 Dutch influenza A(H3N2) viruses characterised by common amino acid substitutions I176M and P386S. The NA of influenza 
A(H1N2) virus is derived from recent HA clade 3C.2a A(H3N2) influenza virus and has in addition the I30L amino acid substitution.
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tracheobronchial epithelial (HTBE) cells with reduced 
amount of virus produced early in infection compared 
to parental A(H3N2) virus [6], suggesting that highly 
likely the current reassortant influenza A(H1N2) virus 
is capable of substantial growth. However, combined 
with the NS segment of influenza A(H1N1)pdm09 virus 
this effect might have an impact on the success of 
isolation of the current reassortant influenza A(H1N2) 
virus, especially when combined with low viral load 
in the clinical specimen. Further phenotypic charac-
terisation of the virus awaits rescue of the virus using 
reverse genetics techniques.
Epidemiological and virological follow-up 
The patient consulted the GP again on 8 March with 
otitis media for which antibiotic treatment (amoxicil-
lin 40 mg/kg 3 daily doses for 7 days) was prescribed. 
Within a few days, the patient made a full recovery. 
Contact investigation revealed that the parents had 
been ill in the last two weeks of February with symp-
toms of gastro-intestinal infection before onset of dis-
ease in the index case. No laboratory diagnostics was 
performed. None of the parents had close contacts with 
animals before the disease episode. The patient visited 
day care a couple of days per week; after onset of dis-
ease, the patient remained at home. In the day care 
centre, more than 20 children from different groups 
(babies 0–1-year-old, toddlers 1–ca 2.5-years-old and 
tots ca 2.5–4-years-old) were reported ill from mid-
January through February. We do not know how many 
of these children had ILI or laboratory-confirmed 
influenza. However, given the fact that the influenza 
epidemic was at its peak at that time, it is likely that 
some of these children had influenza. From the end of 
February, children were reported ill only sporadically. 
In the sentinel surveillance and in the GP and hospital 
laboratory surveillance of influenza virus detections, 
no other influenza A(H1N2) cases were detected up to 
20 March. The main diagnostic laboratory in the region 
was contacted to submit all type A influenza virus-pos-
itive specimens collected in March for subtyping; no 
reassortant viruses were identified among specimens 
from 24 patients; one of them was 5-weeks-old, while 
the rest had a median age of 73 years (range: 31–91 
years).
Discussion 
Human seasonal reassortant A(H1N2) influenza viruses 
harbouring the H1 from human seasonal A(H1N1) and 
seven segments from human seasonal influenza 
A(H3N2) virus have been detected before during an out-
break in China in 1988/89 and from 2000 to 2003 start-
ing in Asia and spreading worldwide [7-10]. However, 
the latter failed to co-circulate in the long term or to 
replace the A(H1N1) or A(H3N2) influenza viruses that 
were in circulation at the time. A sporadic case of sea-
sonal reassortant A(H1N2) influenza virus harbouring 
the H1 from human influenza A(H1N1)pdm09 virus and 
the other seven segments from human seasonal influ-
enza A(H3N2) virus was detected in India during the 
influenza pandemic in 2009 [11]. In a mixture of reas-
sortants generated by in vitro coinfection with sea-
sonal A(H1N1)pdm09 and A(H3N2) influenza viruses, 
sporadic virus with the current 2:6 constellation of 
genome segments was detected [6]. Furthermore, in 
a transmission experiment with guinea pigs infected 
with this mixture of reassortant viruses, the influenza 
A(H1N2) virus with the NS segment from influenza 
A(H1N1)pdm09 virus was not detected in contact ani-
mals [6].
In conclusion, this is the first time a seasonal reassor-
tant A(H1N2) influenza virus with HA and NS from influ-
enza A(H1N1)pdm09 virus and the other six segments 
of influenza A(H3N2) virus is reported in a human natu-
ral infection. The patient recovered fully and there is 
no evidence of extended spreading of the reassortant 
virus in humans. Published evidence indicates lim-
ited capacity for transmission of seasonal reassortant 
A(H1N2) influenza viruses [6,11]. However, laboratories, 
especially national influenza centres, should stay vigi-
lant for reassortant human seasonal influenza viruses 
with mixed genome segments from A(H1N1)pdm09 and 
A(H3N2) influenza viruses.
Figure 4
Phylogenetic analysis of the influenza A(H1N2) virus NS 
genome segment in the context of recent vaccine strains 
and selected seasonal influenza viruses representative of 
those circulating in the Netherlands in 2016 and 2017 and 
in other European countries in January and February 
2018a
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a Sequences were selected from ca 100 influenza A(H1N1)pdm09 
viruses after phylogenetic analysis. We gratefully acknowledge the 
authors, originating and submitting laboratories of the sequences 
retrieved from GISAID’s Epiflu database that were used in this 
analysis (Supplement 2).
Phylogenetic analysis was carried out as described in the Figure 2 
legend. Red dot: influenza A(H1N2) virus described in this study.
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